These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 25155937)

  • 21. Dopamine transporter genotype influences the physiological response to medication in ADHD.
    Gilbert DL; Wang Z; Sallee FR; Ridel KR; Merhar S; Zhang J; Lipps TD; White C; Badreldin N; Wassermann EM
    Brain; 2006 Aug; 129(Pt 8):2038-46. PubMed ID: 16760197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Attention-deficit/hyperactivity disorder: current aspects on pharmacogenetics.
    Rohde LA; Roman T; Hutz MH
    Pharmacogenomics J; 2003; 3(1):11-3. PubMed ID: 12629578
    [No Abstract]   [Full Text] [Related]  

  • 23. High sibling correlation on methylphenidate response but no association with DAT1-10R homozygosity in Dutch sibpairs with ADHD.
    van der Meulen EM; Bakker SC; Pauls DL; Oteman N; Kruitwagen CL; Pearson PL; Sinke RJ; Buitelaar JK
    J Child Psychol Psychiatry; 2005 Oct; 46(10):1074-80. PubMed ID: 16178931
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Personalized medicine and pharmacogenomics in child psychiatry.
    Rockhill C; Althoff RR
    J Am Acad Child Adolesc Psychiatry; 2009 Dec; 48(12):1136. PubMed ID: 20854780
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacogenetic approach for a better drug treatment in children.
    Polanczyk G; Bigarella MP; Hutz MH; Rohde LA
    Curr Pharm Des; 2010; 16(22):2462-73. PubMed ID: 20513229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment.
    Cho SC; Kim BN; Cummins TD; Kim JW; Bellgrove MA
    J Psychopharmacol; 2012 Mar; 26(3):380-9. PubMed ID: 21628343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Genetic bases of attention deficit hyperactivity disorder].
    Sanchez-Mora C; Ribases M; Mulas F; Soutullo C; Sans A; Pamias M; Casas M; Ramos-Quiroga JA
    Rev Neurol; 2012 Nov; 55(10):609-18. PubMed ID: 23143962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Absence of cytogenetic effects in children and adults with attention-deficit/hyperactivity disorder treated with methylphenidate.
    Ponsa I; Ramos-Quiroga JA; Ribasés M; Bosch R; Bielsa A; Ordeig MT; Morell M; Miró R; de Cid R; Estivill X; Casas M; Bayés M; Cormand B; Hervás A
    Mutat Res; 2009 Jun; 666(1-2):44-9. PubMed ID: 19457516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors of placebo response in adults with attention-deficit/hyperactivity disorder: data from 2 randomized trials of osmotic-release oral system methylphenidate.
    Buitelaar JK; Sobanski E; Stieglitz RD; Dejonckheere J; Waechter S; Schäuble B
    J Clin Psychiatry; 2012 Aug; 73(8):1097-102. PubMed ID: 22780962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methylphenidate normalizes elevated dopamine transporter densities in an animal model of the attention-deficit/hyperactivity disorder combined type, but not to the same extent in one of the attention-deficit/hyperactivity disorder inattentive type.
    Roessner V; Sagvolden T; Dasbanerjee T; Middleton FA; Faraone SV; Walaas SI; Becker A; Rothenberger A; Bock N
    Neuroscience; 2010 Jun; 167(4):1183-91. PubMed ID: 20211696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Graphomotor functions in children with attention deficit hyperactivity disorder (ADHD)].
    Stasik D; Tucha O; Tucha L; Walitza S; Lange KW
    Psychiatr Pol; 2009; 43(2):183-92. PubMed ID: 19697788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of actigraphy in the monitoring of methylphenidate versus placebo in ADHD: a meta-analysis.
    De Crescenzo F; Armando M; Mazzone L; Ciliberto M; Sciannamea M; Figueroa C; Janiri L; Quested D; Vicari S
    Atten Defic Hyperact Disord; 2014 Mar; 6(1):49-58. PubMed ID: 24287735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. No significant association between the alpha-2A-adrenergic receptor gene and treatment response in combined or inattentive subtypes of attention-deficit hyperactivity disorder.
    Park S; Kim JW; Kim BN; Hong SB; Shin MS; Yoo HJ; Cho SC
    Pharmacopsychiatry; 2013 Jul; 46(5):169-74. PubMed ID: 23824524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What do dopamine transporter and catechol-o-methyltransferase tell us about attention deficit-hyperactivity disorder? Pharmacogenomic implications.
    Levy F
    Aust N Z J Psychiatry; 2007 Jan; 41(1):10-6. PubMed ID: 17464676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial.
    Cohen-Yavin I; Yoran-Hegesh R; Strous RD; Kotler M; Weizman A; Spivak B
    Clin Neuropharmacol; 2009; 32(4):179-82. PubMed ID: 19644227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genome-wide association study of blood pressure response to methylphenidate treatment of attention-deficit/hyperactivity disorder.
    Mick E; McGough JJ; Middleton FA; Neale B; Faraone SV
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):466-72. PubMed ID: 21130132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bupropion versus methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder: randomized double-blind study.
    Jafarinia M; Mohammadi MR; Modabbernia A; Ashrafi M; Khajavi D; Tabrizi M; Yadegari N; Akhondzadeh S
    Hum Psychopharmacol; 2012 Jul; 27(4):411-8. PubMed ID: 22806822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder.
    Faraone SV; Spencer T; Aleardi M; Pagano C; Biederman J
    J Clin Psychopharmacol; 2004 Feb; 24(1):24-9. PubMed ID: 14709943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder.
    Wilens TE
    J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S46-53. PubMed ID: 18480677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.